Printer Friendly

LEDERLE EXTENDS PROSTEP REBATE THROUGH END OF YEAR TO MAKE PRESCRIPTION NICOTINE PATCH MORE ACCESSIBLE IN LIGHT OF FDA BAN ON OVER-THE-COUNTER SMOKING CESSATION AIDS

 Rebate Extension Allows More Smokers to Consider ProStep Therapy
 as Smoking Cessation Options Narrow
 WAYNE, N.J., June 4 /PRNewswire/ -- Responding to Wednesday's Food and Drug Administration (FDA) announcement banning over-the-counter smoking cessation aids because they have not been shown to be effective, Lederle Laboratories today announced an extension of its unique rebate program for prescription ProStep(R) nicotine transdermal system therapy to Dec. 31, 1993. This extension will enable more smokers to take advantage of ProStep nicotine patch therapy throughout the rest of the year as the number of smoking cessation alternatives are restricted. The rebate program was previously in effect until June 30.
 The FDA banned the shipment of non-prescription smoking cessation aids after determining that they are not effective in helping people quit smoking. Prescription products, such as ProStep, are not affected by the ban, which takes effect on Dec. 1, 1993.
 Lederle will rebate to any eligible patient who begins ProStep therapy by Dec. 31, 1993 and completes a minimum of six continuous weeks of therapy, $1.50 a day, making the cost of a ProStep nicotine patch equal to the average cost of a pack of branded cigarettes. This rebate results in a $63 savings on a six week course of therapy. Eligible patients must save their box tops and register receipts from a minimum of six continuous weeks of ProStep therapy, and mail these materials along with their name, address and phone number, printed legibly, to ProStep Rebate, P.O. Box 15921, Cincinnati, Ohio, 45215-9998. Interested consumers can call, free of charge, 800-678-7837 and interested physicians and pharmacists can call 800-551-7837. After calling the toll-free number, consumers will receive written information on the ProStep Rebate Program. The rebate should be mailed directly to the patient within four to six weeks.
 "As a result of the FDA ban on over-the-counter smoking cessation aids, millions of American smokers may lose confidence in these products, and will eventually have fewer options to help them go through the difficult quitting process," said Edward V. Fritzky, president, Lederle Laboratories. "To provide these smokers with more of an opportunity than ever before to take advantage of ProStep therapy, we are extending the ProStep rebate program so that the average price of a ProStep nicotine patch - $4.00 - is reduced to the average price of a pack of branded cigarettes - $2.50 - for the rest of the year."
 ProStep, available by a doctor's prescription only, is an aid to smoking cessation for the relief of nicotine withdrawal symptoms. ProStep should be used as part of a comprehensive behavioral smoking cessation program.
 The ProStep Rebate Program, an unprecedented corporate initiative, was instituted on March 4, 1993 in response to the phenomenal positive public reaction (including tens of thousands of phone calls) to the Feb. 23 announcement that Lederle is donating 2 million ProStep nicotine patches free of charge to the Association of State and Territorial Health Officials (ASTHO). The ProStep therapy will be provided to state health departments for distribution to state, county and local health departments, as well as other community smoking cessation programs throughout the U.S. In addition to announcing the Rebate Program, Lederle also donated an additional one million ProStep patches to ASTHO, bringing the total number of donated patches to three million.
 The Rebate Program was designed to make ProStep more readily accessible to eligible smokers who want to quit but aren't able to access free ProStep through the ASTHO donation to health departments. This extraordinary rebate program essentially enables eligible smokers to trade their nicotine addiction for a potential cure for that addiction -- ProStep therapy. The extension of the rebate program will now make ProStep therapy more of an option for the many American smokers considering an over-the-counter smoking cessation aid.
 "The public response to the ProStep Rebate Program has been very favorable," said Mr. Fritzky. As of May 31, over 6,300 smokers have called for information on the program, demonstrating to us that the rebate encourages smokers to try ProStep to help them quit. As the choice of smoking cessation aids narrows, we anticipate that the rebate will make ProStep a more realistic choice of therapy for even more American smokers who want to try to quit."
 ProStep rebates are not available for prescriptions reimbursed under Medicaid, similar federal or state programs, other private reimbursement programs or where prohibited by law.
 Lederle's donation of three million ProStep nicotine patches to ASTHO, as well as the ProStep Rebate Program, are extensions of its ongoing commitment to smoking cessation. These actions are also a response to the January Environmental Protection Agency (EPA) report classifying second hand tobacco smoke as a human carcinogen, as well as several other recent studies citing new evidence that smoking and passive smoke pose health risks not only to smokers, but also their spouses, friends, co-workers and their children.
 Lederle Laboratories, a division of American Cyanamid Company, is a research-intensive organization that manufactures and markets worldwide a broad range of healthcare products, including ethical pharmaceuticals, generics, vitamins and nutritionals.
 NOTE:
 -- Please consult full prescribing information.
 -- Patients should not smoke or use other nicotine-containing products during ProStep treatment. ProStep should not be used continuously for more than three months. The effects of ProStep on fetal development are unknown. Therefore, pregnant or nursing smokers should be encouraged to attempt smoking cessation using educational and behavioral interventions before using pharmacological approaches. The benefits of nicotine replacement in cardiovascular or peripheral vascular disease should be carefully weighted against the risks. Since patients on concomitant medication may need dosage adjustment, it is important to ask patients if they are taking any other medications. Consult full prescribing information.
 -0- 6/4/93
 /CONTACT: Jeff Hoyak, 201-831-4619, or Pat Fiaschetti, 201-831-4684, both of Lederle Laboratories/
 (ACY)


CO: Lederle Laboratories ST: New Jersey IN: MTC SU:

PS -- NY010 -- 5355 06/04/93 10:01 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 4, 1993
Words:975
Previous Article:"TATOU QUITS ASPEN, HEADS FOR D.C."
Next Article:FILO APPROVES CAPITAL INCREASE, NEW RIGHTS OFFER
Topics:


Related Articles
CYGNUS SHIPS ITS NICOTINE PATCH
LECTEC RESPONDS TO FDA ADVISORY PANEL INVESTIGATING REPORTS OF ADVERSE REACTIONS OF NICOTINE PATCHES
LEDERLE REBATING ONE-THIRD THE COST OF PROSTEP(R) NICOTINE PATCH THERAPY, AND DONATING 1 MILLION MORE PATCHES TO ASTHO
OTC SMOKING DETERRENTS
SMITHKLINE BEECHAM RECEIVES CLEARANCE TO MARKET NICORETTE WITHOUT A PRESCRIPTION AS AN AID IN SMOKING CESSATION
CYGNUS' NICOTROL(R) RECEIVES FDA ADVISORY PANEL RECOMMENDATION FOR OVER-THE-COUNTER SALE
IN RESPONSE TO MEDIA INQUIRIES REGARDING THE MARKETING APPROVAL OF NICOTROL, SMITHKLINE BEECHAM ISSUED THE FOLLOWING STATEMENT:
THE FOOD AND DRUG ADMINISTRATION APPROVES SMITHKLINE BEECHAM'S NICODERM CQ FOR OVER-THE-COUNTER USE
SmithKline Beecham's NicoDerm CQ Now Available in Stores: Number One Prescription Nicotine Patch Available Over-the-Counter
SmithKline Beecham Comments on Zyban Approval

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters